NGS 기반 RNA-Seq 시장 규모는 2023년에 31억 7,000만 달러로 평가되고 2031년에는 128억 1,000만 달러에 달할 것으로 예상되며, 2024년부터 2031년까지 연평균 19.05%의 성장률을 보일 것으로 예상됩니다. NGS 기반 RNA-Seq(차세대 시퀀서 기반 RNA 시퀀싱)은 시료의 전체 RNA 함량을 철저하게 조사하고 정량화할 수 있는 기술로, RNA를 cDNA 단편 라이브러리로 변환하고 이를 하이스루풋 시퀀싱을 통해 읽어내어 기존 및 신규 전사체를 발견하고 NGS 기반 RNA-Seq는 기초 연구 및 임상 진단 등 다양한 용도로 활용되고 있으며, 연구에서는 다양한 상황에서 다양한 종류의 RNA를 분석할 수 있습니다. 연구에서는 다양한 상황에서의 유전자 발현 패턴을 조사하고, 질병의 원인을 분자 수준에서 이해하며, 미래의 치료 타겟을 찾는 데 사용됩니다.
또한, 병원균의 검출과 특성화를 가능하게함으로써 감염병 연구와 작물 및 가축의 유전자 개량을 위한 농업에도 유용하게 활용될 수 있습니다.
NGS 기반 RNA-Seq 시장을 형성하고 있는 주요 시장 역학
기술의 진보:
차세대 염기서열 분석(NGS) 기술의 지속적인 개선으로 RNA 시퀀싱의 속도와 정확도가 향상되는 동시에 비용이 크게 절감되었습니다. 이로 인해 NGS 기반 RNA-Seq는 연구 및 임상 진단에 더욱 유용하고 선호도가 높아져 시장 성장을 견인하고 있습니다.
개별화 의료에 대한 수요 증가:
NGS 기반 RNA-Seq는 맞춤형 치료법 개발에 필요한 질병의 유전적 기반을 이해하는 데 필수적인 요소로 자리 잡고 있습니다. 맞춤형 치료 접근법이 강조되면서 임상 현장에서 RNA-Seq에 대한 수요가 증가하고 있습니다.
유전자 조사의 증가:
특히 암, 신경학, 감염 등 유전학 연구가 증가하고 있으며, NGS 기반 RNA-Seq는 유전자 발현, 조절, 스플라이싱에 대한 심층적인 인사이트를 제공함으로써 이러한 연구 분야의 발전을 가능하게 하고 시장을 촉진하고 있습니다.
신약 개발 및 신약 개발의 응용 확대:
NGS 기반 RNA-Seq는 새로운 치료 표적을 찾고 유전체 수준에서 약물 반응을 더 잘 이해하기 위해 의약품 연구 및 개발에 점점 더 많이 활용되고 있습니다. 이 응용 분야는 RNA-Seq 시장의 주요 촉진요인입니다.
주요 과제:
높은 데이터 관리 요구 사항:
NGS 기반 RNA-Seq에서는 대량의 데이터가 생성되기 때문에 데이터 저장, 관리, 분석에 큰 장애물이 있습니다. 데이터를 다루고 이해하기 위한 고급 생물정보학 도구와 지식의 필요성은 소규모 연구소나 연구기관에 큰 장애물이 되어 시장 성장을 제한하고 있습니다.
샘플 조제의 복잡성:
NGS 기반 RNA-Seq의 샘플 조제는 복잡하고 오류가 발생하기 쉬워 결과의 정확도에 영향을 미칩니다. 이러한 복잡성으로 인해 숙련된 직원이 필요하고, RNA 시퀀싱 작업에 소요되는 시간과 비용이 증가하여 시장 수요가 감소합니다.
비용 제약:
NGS 장비의 초기 비용과 시약, 유지보수, 데이터 처리에 소요되는 지속적인 비용은 NGS 기술의 비용이 감소하고 있지만, 특정 조직이 감당하기에는 여전히 부담스러운 수준입니다. 이는 자원에 제약이 있는 환경에서 RNA-Seq의 보급을 가로막고 있습니다.
주요 동향:
인공지능과 머신러닝의 통합:
NGS 기반 RNA-Seq에서 AI와 ML 기술의 활용은 대량의 데이터를 효율적으로 관리하고 분석하기 위해 점점 더 널리 보급되고 있습니다. 이러한 도구는 유전자 발현 데이터의 복잡한 패턴을 식별하여 연구 성과와 진단 정확도를 향상시키는 데 도움이 됩니다.
단일 세포 RNA 시퀀싱(scRNA-Seq)의 성장:
단일 세포 RNA 시퀀싱은 시료 내 세포의 돌연변이 및 기능을 보다 정확하게 조사할 수 있기 때문에 수요가 빠르게 증가하고 있습니다. 이러한 추세는 단일 세포 수준에서 생물학 및 질병에 대한 이해를 근본적으로 변화시키고 있습니다.
멀티플렉싱 및 하이스루풋 기술:
멀티플렉싱과 하이스루풋 시퀀싱 기술을 통해 많은 샘플과 유전자를 동시에 분석할 수 있게 되었습니다. 이는 효율성이 향상되고 샘플당 비용이 감소하여 RNA-Seq가 더욱 친숙해지고 연구 및 임상 진단에 널리 사용되어 시장 확장을 촉진할 수 있습니다.
임상 진단으로 확대:
유전체 수준에서 질병을 발견하고 이해하기 위해 임상 진단에서 NGS 기반 RNA-Seq를 사용하는 경향이 증가하고 있습니다. 여기에는 암 진단, 감염, 유전자 이상에 대한 적용이 포함되며, 보다 개인화되고 효과적인 치료의 길을 열어줄 수 있습니다.
NGS-based RNA-seq Market size was valued at USD 3.17 Billion in 2023 and is projected to reach USD 12.81 Billion by 2031 , growing at a CAGR of 19.05% from 2024 to 2031. NGS-based RNA-seq (Next-Generation Sequencing-based RNA sequencing) is a technology that enables a thorough investigation and quantification of a sample's total RNA content. NGS-based RNA-seq converts RNA into a library of cDNA fragments that are then read using high-throughput sequencing methods, which can discover known and novel transcripts, quantify gene expression levels, and uncover alternative splicing events, among other findings. NGS-based RNA-seq has many applications, including basic research and clinical diagnostics. In research, it is used to investigate gene expression patterns under various situations, gain a molecular understanding of disease causes, and find prospective treatment targets
Furthermore, it is useful in the research of infectious illnesses by allowing for pathogen detection and characterization, as well as in agriculture for crop and livestock genetic improvement.
The key market dynamics that are shaping the NGS-based RNA-seq Market include:
Technological Advancements:
The constant improvement of Next-Generation Sequencing (NGS) technologies has greatly decreased costs while increasing the speed and accuracy of RNA sequencing. This makes NGS-based RNA-seq more accessible and desirable for research and clinical diagnostics, resulting in increased market growth.
Increased Demand for Personalized Medicine:
NGS-based RNA-seq has become crucial for understanding the genetic basis of diseases, which is required for the development of personalized therapy. The rising emphasis on individualized treatment approaches drives up the need for RNA-seq in clinical settings.
Rise in Genetic Research:
There is an increase in genetic research, particularly in cancer, neurology, and infectious disorders. NGS-based RNA-seq gives detailed insights into gene expression, regulation, and splicing, allowing for advances in these study domains and propelling the market.
Expanding Applications in Drug Discovery and Development:
NGS-based RNA-seq is increasingly being utilized in drug research and development to find new therapeutic targets and better understand drug responses at the genomic level. This application is a major driver of the RNA-seq market.
Key Challenges:
High Data Management Requirements:
NGS-based RNA-seq creates massive volumes of data, which presents substantial hurdles in data storage, management, and analysis. This need for sophisticated bioinformatics tools and knowledge to handle and understand data becomes a significant hurdle for smaller laboratories and research institutes, limiting market growth.
Complexity of Sample Preparation:
Sample preparation for NGS-based RNA-seq is complex and error-prone, affecting the accuracy of results. This complexity demands trained staff and increases the time and expense involved with RNA sequencing initiatives, reducing market demand.
Cost Constraints:
The original cost of NGS equipment and continuing expenses for reagents, maintenance, and data processing, even with NGS technology' declining costs, remain unaffordable for certain organizations. This hinders the widespread deployment of RNA-seq in resource-constrained environments.
Key Trends:
Integration of Artificial Intelligence and Machine Learning:
The use of AI and ML technologies in NGS-based RNA-seq is becoming increasingly popular for efficiently managing and analyzing large amounts of data. These tools help to identify complicated patterns in gene expression data for improving research outcomes and diagnosis accuracy.
Single-Cell RNA Sequencing (scRNA-seq) Growth:
Demand for single-cell RNA sequencing is quickly increasing since it allows for a more precise investigation of cellular variations and functions within a sample. This trend is fundamentally changing our understanding of biology and disease at the single-cell level.
Multiplexing and High-Throughput Technologies:
Multiplexing and high-throughput sequencing technologies have made it possible to analyze many samples or genes at the same time. This increases efficiency and lowers the cost per sample, making RNA-seq more accessible and widely used in research and clinical diagnoses, promoting market expansion.
Expansion into Clinical Diagnostics:
There is an increasing trend of using NGS-based RNA-seq in clinical diagnostics to discover and understand disorders at the genomic level. This includes applications in cancer diagnoses, infectious diseases, and genetic abnormalities, paving the path for more personalized and effective therapies.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Here is a more detailed regional analysis of the NGS-based RNA-seq Market:
North America:
According to Verified Market Research, North America is estimated to dominate in NGS-based RNA-seq Market over the forecast period. North America, particularly the United States, has a strong research infrastructure, including multiple top universities, research organizations, and biotech companies. This climate promotes innovation and rapid adoption of NGS-based RNA-seq technologies, allowing the region to dominate the market
Significant public and private investment in the healthcare and biotechnology industries in North America enables advanced research, development, and application of NGS-based RNA-seq. This financial support speeds up technical breakthroughs and their implementation in healthcare settings.
Personalized medicine is becoming increasingly popular in North America, to tailor medical treatments to individual genetic profiles. NGS-based RNA-seq is critical for understanding genetic variants, thereby, driving its use in both research and clinical diagnostics throughout the region.
Furthermore, the regulatory climate in North America, particularly in the United States, fosters the development and application of NGS-based technologies, thanks to the FDA's proactive approach to genomic and precision medicine. This supporting policy framework shortens the path to market for innovative RNA-seq applications and developments.
Asia Pacific:
Asia Pacific is estimated to grow at the highest CAGR within the NGS-based RNA-seq Market during the forecast period. The region's healthcare sector is expanding rapidly, supported by increased investment and government measures to improve healthcare infrastructure. This expansion encourages the use of modern technologies such as NGS-based RNA-seq in diagnosis and research.
Precision medicine is becoming increasingly important in Asia Pacific countries, to provide patient-specific medicines based on genetic information. As a result of its importance in studying genetic variants, NGS-based RNA-seq is becoming increasingly popular.
The region is experiencing an increase in the prevalence of genetic abnormalities and cancer, necessitating the use of modern diagnostic technologies. NGS-based RNA-seq provides extensive insights into genetic information, allowing for early detection and personalized treatment regimens.
Furthermore, Asia-Pacific is emerging as a hub for biotechnology and pharmaceutical research and development. Governments and commercial organizations are increasing financing for genomics research, accelerating the expansion of NGS-based RNA-seq by providing critical resources for innovation and application in this field.
Europe:
Europe has a rich legacy of international collaborative research, which is encouraged by EU financing programs such as Horizon Europe. These efforts promote the use of NGS-based RNA-seq technologies in a variety of sectors, accelerating growth by pooling resources and expertise.
European countries are investing more in precision medicine, with national and regional initiatives aimed at incorporating genomic data into healthcare. NGS-based RNA-seq is critical for these activities, resulting in increased application in both research and clinical diagnoses.
The most recent genomics technology advancements are being quickly adopted by the European market. This includes NGS-based RNA-seq, which is growing and becoming more accessible across the region because of advances in sequencing efficiency, data processing, and cost reductions, driving market adoption.
Furthermore, the biotech and pharmaceutical industries in Europe are expanding rapidly, with an emphasis on medication discovery and development using genomic data. NGS-based RNA-seq is critical for discovering new therapeutic targets and understanding disease mechanisms, driving its development in these industries.
The NGS-based RNA-seq Market is Segmented based on Product & Service, Technology, Application, End-user, And Geography.
Based on Product & Service, the market is segmented into Sample Preparation Products, Sequencing Platforms and Consumables, Sequencing Services, and Data Analysis, Storage & Management. The sequencing platforms and consumables segment is estimated to dominate the NGS-based RNA-seq Market due to the critical function these products play throughout the sequencing process. Sequencing platforms and consumables are critical components of RNA sequencing because they have a direct impact on the efficiency, accuracy, and throughput of the sequencing procedures. The high costs of these platforms, along with the continuous requirement for consumables, ensure that this category receives a sizable share of market income.
Based on Technology, the market is segmented into Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing, and Nanopore Sequencing. The sequencing by synthesis (SBS) segment is estimated to grow at the highest CAGR in the NGS-based RNA-seq Market due to its widespread use in academic research and clinical diagnostics due to its high throughput, precision, and cost-effectiveness when compared with other sequencing methods. SBS, as demonstrated by Illumina's sequencing platforms, has established the gold standard in NGS because it delivers a consistent balance of read length and sequencing depth, making it ideal for a wide range of applications, including transcriptome profiling and whole-genome sequencing.
Based on Application, the market is segmented into Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, and Variant Calling & Transcriptome Epigenetics. The expression profiling analysis segment is estimated to exhibit the highest growth within the market over the forecast period due to the crucial role that expression profiling plays in understanding gene function, regulation, and the genetic basis of illness. Expression profiling analysis using NGS-based RNA-seq offers unprecedented depth and breadth in assessing the expression levels of thousands of genes at the same time, providing insights into the molecular signatures of distinct cells and tissues under varied settings.
Based on End-User, the market is segmented into Research and Academia, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Others. The research and academia segment is estimated to grow at the highest CAGR in the market over the forecast period owing to the widespread use of NGS-based RNA sequencing in basic and applied research to get an unprecedented understanding of genomic expressions, variants, and functions. Globally, academic and research organizations make significant investments in genomic research, using RNA-seq technology to investigate difficult biological problems, disease processes, and evolutionary studies.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.